Skip to content
The Policy VaultThe Policy Vault

tobramycin sulfate — CareFirst (Caremark)

Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus species, E. coli, Klebsiella species, Enterobacter species, and S. aureus

Initial criteria

  • Bacterial cultures are obtained prior to and during treatment to identify etiologic organisms and test susceptibility to tobramycin
  • Patient has a proven or strongly suspected infection caused by bacteria susceptible to tobramycin
  • If causative organisms are resistant to tobramycin, other appropriate therapy should be used
  • In serious life‑threatening gram‑negative infections, tobramycin may be initiated empirically before susceptibility results are available; continuation must be based on susceptibility and clinical response